Skip to main content

Day: May 27, 2021

Foresight VCT plc – AGM Statement

AGM Statement The Board of Foresight VCT plc is pleased to announce that at the Annual General Meeting of the Company held on 27 May 2021 all of the resolutions were duly passed. The proxy voting was as follows:Resolution Votes For (or at the Chairman’s discretion) Votes Against1 – To Receive the Report and Accounts 11,358,267 (98.78%) 140,776 (1.22%)2 – Approval of the Directors’ Remuneration Report 10,744,004 (95.38%) 520,902 (4.62%)3 – Approval of the Directors’ Remuneration Policy 10,694,652 (95.60%) 492,768 (4.40%)4 – To re-elect Gordon Humphries as director 10,895,617 (96.48%) 397,481 (3.52%)5 – To re-elect Jocelin Harris as director 10,907,200 (96.53%) 392,313 (3.47%)6 – To re-elect Margaret Littlejohns as director 11,018,404 (97.39%) 294,781 (2.61%)7 –...

Continue reading

Gentex Awarded Technology & Development Award from Toyota Motor Corporation for Its Mirror-Integrated Digital Video Recorder

Toyota Display Mirror with Integrated DVRToyota Motor Corporation recently recognized Gentex with an award for its innovative Full Display Mirror with built-in digital video recorder.ZEELAND, Mich., May 27, 2021 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass and fire protection technologies, was recently named a 2020 Technology and Development Award winner by Toyota Motor Corporation. This award recognizes automotive suppliers for superior innovation and product development efforts. Gentex was recognized for its digital video recorder (DVR) system, which launched in 2020 on the Toyota Harrier in Japan. The DVR system is built into a Gentex Full Display Mirror®, or FDM®, a digital rearview mirror that uses a custom camera and mirror-integrated...

Continue reading

Cortland Bancorp Again Listed by American Banker Magazine as One of Top 200 Publicly Traded Community Banks and Thrifts

Local bank ranked #86 in 2021, up from #105 in 2020 CORTLAND, Ohio, May 27, 2021 (GLOBE NEWSWIRE) — Cortland Bancorp. (NASDAQ: CLDB), the bank holding company of The Cortland Savings and Banking Company, today announced that, for the third straight year, it was again named to American Banker magazine’s Top 200 Publicly Traded Community Banks and Thrifts. In its May 2021 issue, American Banker ranked Cortland Bancorp 86th on the list of top performing publicly traded community banks. This continues the Bank’s upward growth trajectory after ranking as #105 on last year’s list and #134 in 2019. The rankings are based on three-year average return on equity (ROE) as of the end of the previous year. “It is always a great honor to be recognized by American Banker,” said James M. Gasior, President and Chief Executive Officer. “This type...

Continue reading

Mortgage Rates Drop Below Three Percent

Primary Mortgage Market Survey®U.S. weekly average mortgage rates as of May 27, 2021.MCLEAN, Va., May 27, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing that the 30-year fixed-rate mortgage (FRM) averaged 2.95 percent. “Mortgage rates are down below three percent, continuing to offer many homeowners the potential to refinance and increase their monthly cash flow,” said Sam Khater, Freddie Mac’s Chief Economist. “In fact, homeowners who refinanced their 30-year fixed-rate mortgage in 2020 saved more than $2,800 dollars annually. Substantial opportunity continues to exist today, as nearly $2 trillion in conforming mortgages have the ability to refinance and reduce their interest rate by at least half a percentage point.” News Facts30-year...

Continue reading

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Company’s 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks. Innovation Pharma is developing Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients under U.S. FDA Fast Track designation (see NCT04784897). The Phase 2 study is a randomized, double-blind, placebo-controlled clinical trial evaluating Brilacidin, a synthetic, non-peptidic small molecule drug candidate in a new class of compounds called defensin-mimetics, at domestic and international sites. The Company intends to provide...

Continue reading

Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will participate in a live, virtual fireside chat at the 41st Annual William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 4:20 PM ET. Jack Kenny will also pre-record a presentation for the Jefferies Virtual Healthcare Conference which will be webcast on Friday, June 4, 2021 at 2:00 PM ET. Jack Kenny will be taking 1×1 meetings at the William Blair conference while Bryan Baldasare, Executive Vice President and Chief Financial Officer, and Charlie Wood, Vice President – Investor Relations, are taking 1×1 meetings at the Jefferies conference.   To access these presentations, go the Events & Presentations section of...

Continue reading

Zealand Pharma launches long-term incentive program for Zealand’s US based Corporate Management for 2021

Company announcement – No. 33 / 2021 Zealand Pharma launches long-term incentive program for Zealand’s US based Corporate Management for 2021 Copenhagen, DK and Boston, MA, U.S., May 27, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announces the implementation of a new share-based long-term incentive program for Zealand’s US based Corporate Management, in accordance with Zealand’s Remuneration Policy as adopted at the annual general meeting held on 15 April 2021. Zealand implemented the new incentive program to align with selected biotech peers, and is intended to drive long-term performance, align management’s and employees’ interests with those of Zealand’s shareholders,...

Continue reading

Coro to Democratize Access to Gold in Nevada – The Real Golden State.

Miami, Florida, May 27, 2021 (GLOBE NEWSWIRE) — Coro Global Inc. (OTCQB: CGLO) announced today that its subsidiary Coro Corp., was granted a U.S. Money Transmitter license the State of Nevada. The company created CORO, a mobile payment app that allows anyone to exchange, send and save gold and dollars easily and securely. Coro Global is a Florida-based fintech on a mission to support people in understanding the value of using gold as resilient money. Coro is leveraging deep financial know-how and the new generation of distributed ledger technology (hashgraph) to build the infrastructure and tools for anyone to be able to buy gold in the smallest denominations and use it as easily as traditional currencies in their everyday lives. Nevada has a long history with gold. Its trajectory and wealth were built on prolific gold and silver...

Continue reading

Amazonas Florestal, Ltd Releases Update to Recent Company Activity

Miami, FL, May 27, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Amazonas Florestal, Ltd (OTC: AZFL), a natural resources company dedicated to the processing of Industrial Hemp, High-CBD Hemp Products and the preservation of rainforest properties in Brazil that are eligible for REDD Plus Carbon Credits—a United Nations program—announced a recap of recent company material events. Recently the Company returned to current and compliant status with OTC Markets as a Pink Sheets Information Tier Company, having reorganized after a period of almost 3 years. Management is currently working diligently with hired accountants to complete a PCAOB audit of its records that should be completed in the month of July 2021. The completion of the PCAOB audit is the final requirement for the company to become eligible for funding facilities that...

Continue reading

Form 8.3 -Xeris Pharmaceuticals Inc 27 May 2021

                FORM 8.3   IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION  Name of person dealing (Note 1) State Street Global Advisors & AffiliatesCompany dealt in Xeris Pharmaceuticals IncClass of relevant security to which the dealings being disclosed relate (Note 2) $0.001 common stockDate of dealing 26th May 2021       2. INTERESTS AND SHORT POSITIONS   (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)    Long Short  Number (%) Number (%)(1) Relevant securities 1,001,3261.50866%   (2) Derivatives (other than options) N/A      (3) Options and agreements to purchase/sell N/A      Total 1,001,326...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.